Keith Layden, Non Executive Director, sold post-exercise 1,527 shares in the company on the 10th March 2020 at a price of 4483.84p. The Director now...

Jez Maiden, Financial Director, exercised 14,333 shares in the company on the 9th March 2020 at a price of 0.00p. The Director now holds 42,274...

Jez Maiden, Financial Director, sold post-exercise 6,751 shares in the company on the 10th March 2020 at a price of 4483.84p. The Director now holds...

Iain McLaren, Non Executive Director, has re-invested 258 shares in the company on the 12th March 2020 at a price of 146.97p. The Director now...

It may be unlucky for some but for UK investors Friday 13th provided welcome relief after a week of brutal losses which saw $8trn wiped...

Jean-Philippe Mouton, Director, exercised 36,474 shares in the company on the 12th March 2020 at a price of 0.00p. The Director now holds 452,827 shares....

Steve Foots, Chief Executive Officer, exercised 27,209 shares in the company on the 9th March 2020 at a price of 0.00p. The Director now holds...

Steve Foots, Chief Executive Officer, sold post-exercise 12,814 shares in the company on the 10th March 2020 at a price of 4483.84p. The Director now...

Keith Layden, Non Executive Director, exercised 3,241 shares in the company on the 9th March 2020 at a price of 0.00p. The Director now holds...

RBC Capital Markets today reaffirms its sector performer investment rating on Dechra Pharmaceuticals PLC (LON:DPH) and raised its price target to 2530p (from 2500p).

Broker...